Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Pediatrics Reports
Erschienen in:

01.06.2019 | Cardiology (W Zuckerman and E Silver, Section Editors)

Pulmonary Hypertension in Children with Sickle Cell Disease: a Review of the Current Literature

verfasst von: Jamie K. Harrington, Usha S. Krishnan

Erschienen in: Current Pediatrics Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Pulmonary hypertension (PH) is a well-recognized complication of sickle cell disease (SCD) and is one of the strongest predictors of increased morbidity and mortality in adult patients. There is evidence that PH can develop in children with SCD and the clinical implications of this finding are an area of active research. We review the current literature examining the association of SCD and PH in childhood.

Recent Findings

The recent literature has focused on elucidating the multifactorial mechanisms for the development of PH in SCD with the goal of developing targeted therapies. In addition, there has been a focus on understanding the significance of echocardiographic evidence of PH in children with SCD, a finding that has recently been associated with adverse clinical factors. While still based on limited evidence, the increased understanding of the important prognostic implications of echocardiographic evidence of PH has led to the development of guidelines that recommend screening echocardiograms beginning in childhood in children with SCD.

Summary

PH can develop in children with SCD and, while the exact clinical implications of this finding are still being elucidated, current guidelines and research are aimed at early identification and treatment to improve outcomes.
Literatur
1.
Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat Rev Dis Prim . 2018;4:18010.
2.
Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010 ;376:2018–31.
3.
Miller AC, Gladwin MT. Pulmonary Complications of Sickle Cell Disease. Am J Respir Crit Care Med. 2012;185:1154–65.
4.
Gladwin MT, Sachdev V. Cardiovascular Abnormalities in Sickle Cell Disease. J Am Coll Cardiol. 2012;59:1123–33.
5.
Gladwin MT. Cardiovascular complications in patients with sickle cell disease. Hematol Am Soc Hematol Educ Progr. 2017;2017:423–30.
6.
Gladwin MT. Cardiovascular complications and risk of death in sickle-cell disease. Lancet. 2016;387:2565–74.
7.
Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease. N Engl J Med. 2004;350:886–95.
8.
Gladwin MT, Barst RJ, Gibbs JSR, Hildesheim M, Sachdev V, Nouraie M, et al. Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. West J, editor. PLoS One. 2014;9:e99489.
9.
Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ. Mortality in Adults With Sickle Cell Disease and Pulmonary Hypertension. JAMA. 2012;307:1254.
10.
Mehari A, Alam S, Tian X, Cuttica MJ, Barnett CF, Miles G, et al. Hemodynamic Predictors of Mortality in Adults with Sickle Cell Disease. Am J Respir Crit Care Med. 2013;187:840–7.
11.
Damy T, Bodez D, Habibi A, Guellich A, Rappeneau S, Inamo J, et al. Haematological determinants of cardiac involvement in adults with sickle cell disease†. Eur Heart J. 2015;37:1158–67.
12.
Castro O, Minniti CP, Nouraie M. Pulmonary Hypertension in Sickle Cell Disease. N Engl J Med. 2011;365:1645–9.
13.
McLaughlin V V., Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. J Am Coll Cardiol [Internet]. Journal of the American College of Cardiology. 2009;53:1573–619.
14.
Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37:67–119.
15.
Upadhya B, Stacey RB, Ntim W, Knovich MA, Pu M. Echocardiography-Derived Tricuspid Regurgitant Jet Velocity Is an Important Marker for the Progression of Sickle-Cell Disease. Acta Haematol. 2014;132:152–8.
16.
Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease. Pediatrics. 2008;121:777–82.
17.
Ambrusko SJ, Gunawardena S, Sakara A, Windsor B, Lanford L, Michelson P, et al. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatr Blood Cancer. 2006;47:907–13.
18.
Colombatti R, Maschietto N, Varotto E, Grison A, Grazzina N, Meneghello L, et al. Pulmonary hypertension in sickle cell disease children under 10 years of age. Br J Haematol. 2010;150:601–9.
19.
Musa BM, Galadanci NA, Coker M, Bussell S, Aliyu MH. The global burden of pulmonary hypertension in sickle cell disease: a systematic review and meta-analysis. Ann Hematol. 2016;95:1757–64.
20.
Caughey MC, Poole C, Ataga KI, Hinderliter AL. Estimated pulmonary artery systolic pressure and sickle cell disease: a meta-analysis and systematic review. Br J Haematol. 2015;170:416–24.
21.
•• Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, et al. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation. 2015;132:2037–99. This is an executive summary from a committee of experienced clinicians from the American Heart Association and American Thoracic Society summarizing and appraising the relevant literature, and providing evidence-based recommendations for diagnosis and management of pulmonary hypertension in children, including in sickle cell disease.
22.
• Abman SH, Ivy DD, Archer SL, Wilson K, AHA/ATS Joint Guidelines for Pediatric Pulmonary Hypertension Committee. Executive Summary of the American Heart Association and American Thoracic Society Joint Guidelines for Pediatric Pulmonary Hypertension. Am J Respir Crit Care Med. 2016;194:898–906. This is an executive summary of the longer official guidelines, reference 21, from the American Heart Association and American Thoracic Society joint committee on recommendations for diagnosis and management of pediatric pulmonary hypertension highlighting the key recommendations.
23.
Abman SH. New guidelines for managing pulmonary hypertension. Curr Opin Pediatr. 2016;28:597–606.
24.
Klings ES, Machado RF, Barst RJ, Morris CR, Mubarak KK, Gordeuk VR, et al. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014;189:727–40.
25.
Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of Sickle Cell Disease. JAMA. 2014;312:1033.
26.
Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest [Internet]. American Society for Clinical Investigation. 2017;127:750–60.
27.
Gordeuk VR, Castro OL, Machado RF. Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood. 2016;127:820–8.
28.
Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol. 2009;54:S43–54.
29.
Hatano S, Strasser T. Primary Pulmonary Hypertension: report on a WHO meeting. Geneva: World Heal Organ.
30.
Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol [Internet]. Journal of the American College of Cardiology. 2013;62:D34–41.
31.
Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, Ivy DD, Berger RMF Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019;53.
32.
Graham JK, Mosunjac M, Hanzlick RL, Mosunjac M. Sickle Cell Lung Disease and Sudden Death. Am J Forensic Med Pathol. 2007;28:168–72.
33.
Manci EA, Culberson DE, Yang Y-M, Gardner TM, Powell R, Haynes J, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003;123:359–65.
34.
Haque AK, Gokhale S, Rampy BA, Adegboyega P, Duarte A, Saldana MJ. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol. 2002;33:1037–43.
35.
Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, et al. A Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease. N Engl J Med. 2011;365:44–53.
36.
Fonseca GHH, Souza R, Salemi VMC, Jardim CVP, Gualandro SFM. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J. 2012;39:112–8.
37.
Gladwin MT, Machado RF. Pulmonary Hypertension in Sickle Cell Disease. N Engl J Med. 2011;365:1645–9.
38.
Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood. 2011;118:855–64.
39.
Barst RJ, Mubarak KK, Machado RF, Ataga KI, Benza RL, Castro O, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol. 2010;149:426–35.
40.
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2018;53:1801913.
41.
Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and Diagnosis of Pulmonary Hypertension. J Am Coll Cardiol. 2013;62:D42–50.
42.
Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery J-L, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J Off J Eur Soc Clin Respir Physiol. 2009;34:1219–63.
43.
Skinner GJ. Echocardiographic Assessment of Pulmonary Arterial Hypertension for Pediatricians and Neonatologists. Front Pediatr [Internet]. Frontiers Media SA. 2017;5:168.
44.
Jone P-N, Ivy DD. Echocardiography in pediatric pulmonary hypertension. Front Pediatr [Internet]. Frontiers Media SA. 2014;2:124.
45.
Gladwin MT. Revisiting the hyperhemolysis paradigm. Blood. American Society of Hematology. 2015;126:695–6.
46.
Gladwin MT, Barst RJ, Castro OL, Gordeuk VR, Hillery CA, Kato GJ, et al. Pulmonary hypertension and NO in sickle cell. Blood [Internet]. American Society of Hematology. 2010;116:852–4.
47.
Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO, Schechter AN, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8:1383–9.
48.
Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, Diwan BA, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood [Internet]. American Society of Hematology. 2007;109:3088–98.
49.
Rother RP, Bell L, Hillmen P, Gladwin MT. The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin. JAMA. 2005;293:1653.
50.
Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I, et al. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal. Hindawi Limited. 2012;2012:949535.
51.
Zuckerman WA, Rosenzweig EB. Pulmonary hypertension in children with sickle cell disease. Expert Rev Respir Med. 2011;5:233–43.
52.
DeMartino AW, Kim-Shapiro D, Patel RP, Gladwin MT. Nitrite and nitrate chemical biology and signaling. Br J Pharmacol. 2018.
53.
Walford G, Loscalzo J. Nitric oxide in vascular biology. J Thromb Haemost. 2003;1:2112–8.
54.
Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. 2005;294:81–90.
55.
Landburg PP, Teerlink T, Biemond BJ, Brandjes DPM, Muskiet FAJ, Duits AJ, et al. Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype. Blood Cells, Mol Dis. 2010;44:229–32.
56.
Kalra VK, Zhang S, Malik P, Tahara SM. Placenta growth factor mediated gene regulation in sickle cell disease. Blood Rev. 2018;32:61–70.
57.
Bilan VP, Schneider F, Novelli EM, Kelley EE, Shiva S, Gladwin MT, et al. Experimental intravascular hemolysis induces hemodynamic and pathological pulmonary hypertension: association with accelerated purine metabolism. Pulm Circ. 2018;8:204589401879155.
58.
Conran N, Belcher JD. Inflammation in sickle cell disease. Connes P, ed. Clin Hemorheol Microcirc. 2018;68:263–99.
59.
Figueiredo RT, Fernandez PL, Mourao-Sa DS, Porto BN, Dutra FF, Alves LS, et al. Characterization of heme as activator of Toll-like receptor 4. J Biol Chem [Internet]. American Society for Biochemistry and Molecular Biology. 2007;282:20221–9.
60.
Dutra FF, Alves LS, Rodrigues D, Fernandez PL, de Oliveira RB, Golenbock DT, et al. Hemolysis-induced lethality involves inflammasome activation by heme. Proc Natl Acad Sci. 2014;111:E4110–8.
61.
Hebbel RP, Key NS. Microparticles in sickle cell anaemia: promise and pitfalls. Br J Haematol. 2016;174:16–29.
62.
Camus SM, De Moraes JA, Bonnin P, Abbyad P, Le Jeune S, Lionnet F, et al. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood. 2015;125:3805–14.
63.
Gladwin MT, Ofori-Acquah SF. Erythroid DAMPs drive inflammation in SCD. Blood. 2014;123:3689–90.
64.
Mendonça R, Silveira AAA, Conran N. Red cell DAMPs and inflammation. Inflamm Res. 2016;65:665–78.
65.
Tantawy AAG, Adly AAM, Ismail EAR, Habeeb NM, Farouk A. Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: Relation to cardiovascular complications. Platelets. 2013;24:605–14.
66.
Niss O, Quinn CT, Lane A, Daily J, Khoury PR, Bakeer N, et al. Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease. JACC Cardiovasc Imaging. 2016;9:243–52.
67.
Desai AA, Patel AR, Ahmad H, Groth J V., Thiruvoipati T, Turner K, et al. Mechanistic Insights and Characterization of Sickle Cell Disease–Associated Cardiomyopathy. Circ Cardiovasc Imaging. 2014;7:430–7.
68.
Junqueira FP, Fernandes JL, Cunha GM, TA Kubo T, MAO Lima C, BP Lima D, et al. Right and left ventricular function and myocardial scarring in adult patients with sickle cell disease: a comprehensive magnetic resonance assessment of hepatic and myocardial iron overload. J Cardiovasc Magn Reson. 2013;15:83.
69.
Bratis K, Kattamis A, Athanasiou K, Hautemann D, van Wijk K, Reiber H, et al. Abnormal myocardial perfusion–fibrosis pattern in sickle cell disease assessed by cardiac magnetic resonance imaging. Int J Cardiol. 2013;166:e75–6.
70.
Milton JN, Rooks H, Drasar E, McCabe EL, Baldwin CT, Melista E, et al. Genetic determinants of haemolysis in sickle cell anaemia. Br J Haematol. 2013;161:270–8.
71.
Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. Am J Hematol. 2012;87:795–803.
72.
Chang AK, Ginter Summarell CC, Birdie PT, Sheehan VA. Genetic modifiers of severity in sickle cell disease. Connes P, editor. Clin Hemorheol Microcirc. 2018;68:147–64.
73.
Renoux C, Joly P, Faes C, Mury P, Eglenen B, Turkay M, et al. Association between Oxidative Stress, Genetic Factors, and Clinical Severity in Children with Sickle Cell Anemia. J Pediatr. 2018;195:228–35.
74.
Habara A, Steinberg MH. Minireview: Genetic basis of heterogeneity and severity in sickle cell disease. Exp Biol Med. 2016;241:689–96.
75.
Khorshied MM, Mohamed NS, Hamza RS, Ali RM, El-Ghamrawy MK. Protein Z and Endothelin-1 genetic polymorphisms in pediatric Egyptian sickle cell disease patients. J Clin Lab Anal. 2018;32:e22264.
76.
Dahoui HA, Hayek MN, Nietert PJ, Arabi MT, Muwakkit SA, Saab RH, et al. Pulmonary hypertension in children and young adults with sickle cell disease: Evidence for familial clustering. Pediatr Blood Cancer. 2010;54:398–402.
77.
Sokunbi OJ, Ekure EN, Temiye EO, Anyanwu R, Okoromah CAN. Pulmonary hypertension among 5 to 18 year old children with sickle cell anaemia in Nigeria. Tayo BO, editor. PLoS One. 2017;12:e0184287.
78.
Al-Allawi N, Mohammad AM, Jamal S. Doppler-Defined Pulmonary Hypertension in Sickle Cell Anemia in Kurdistan, Iraq. West J, editor. PLoS One. 2016;11:e0162036.
79.
Harrington JK, Krishnan U, Jin Z, Mardy C, Kobsa S, Lee MT. Longitudinal Analysis of Echocardiographic Abnormalities in Children With Sickle Cell Disease. J Pediatr Hematol Oncol. 2017;39:500–5.
80.
Nelson SC, Adade BB, McDonough EA, Moquist KL, Hennessy JM. High Prevalence of Pulmonary Hypertension in Children With Sickle Cell Disease. J Pediatr Hematol Oncol. 2007;29:334–7.
81.
Sedrak A, Rao SP, Miller ST, Hekmat V, Rao M. A Prospective Appraisal of Pulmonary Hypertension in Children With Sickle Cell Disease. J Pediatr Hematol Oncol. 2009;31:97–100.
82.
Onyekwere OC, Campbell A, Teshome M, Onyeagoro S, Sylvan C, Akintilo A, et al. Pulmonary Hypertension in Children and Adolescents with Sickle Cell Disease. Pediatr Cardiol. 2008;29:309–12.
83.
Minniti CP, Sable C, Campbell A, Rana S, Ensing G, Dham N, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica. 2009;94:340–7.
84.
Agha H, El Tagui M, El Ghamrawy M, Hady MA. The 6-min walk test: an independent correlate of elevated tricuspid regurgitant jet velocity in children and young adult sickle cell patients. Ann Hematol. 2014;93:1131–8.
85.
Hebson C, New T, Record E, Oster M, Ehrlich A, Border W, et al. Elevated tricuspid regurgitant velocity as a marker for pulmonary hypertension in children with sickle cell disease: less prevalent and predictive than previously thought? J Pediatr Hematol Oncol. 2015;37:134–9.
86.
Lee MT, Small T, Khan MA, Rosenzweig EB, Barst RJ, Brittenham GM. Doppler-defined pulmonary hypertension and the risk of death in children with sickle cell disease followed for a mean of three years. Br J Haematol. 2009;146:437–41.
87.
Kato GJ, Onyekwere OC, Gladwin MT. Pulmonary hypertension in sickle cell disease: relevance to Children. Pediatr Hematol Oncol. 2007;24:159–70.
88.
Nouraie M, Lee JS, Zhang Y, Kanias T, Zhao X, Xiong Z, et al. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica. 2013;98:464–72.
89.
Elalfy MS, Youssef OI, Deghedy MMR, Abdel Naby MM. Left Ventricular Structural and Functional Changes in Children With β-Thalassemia and Sickle Cell Disease. J Pediatr Hematol Oncol. 2018;40:171–7.
90.
Liem RI, Nevin MA, Prestridge A, Young LT, Thompson AA. Tricuspid regurgitant jet velocity elevation and its relationship to lung function in pediatric sickle cell disease. Pediatr Pulmonol. 2009;44:281–9.
91.
Mondal P, Stefek B, Sinharoy A, Sankoorikal B-J, Abu-Hasan M, Aluquin V. The association of nocturnal hypoxia and an echocardiographic measure of pulmonary hypertension in children with sickle cell disease. Pediatr Res. 2018.
92.
Newaskar M, Hardy KA, Morris CR. Asthma in Sickle Cell Disease. Sci World J. 2011;11:1138–52.
93.
Morris CR. Asthma management: Reinventing the wheel in sickle cell disease. Am J Hematol. 2009;84:234–41.
94.
Minniti CP, Taylor JG, Hildesheim M, O’Neal P, Wilson J, Castro O, et al. Laboratory and echocardiography markers in sickle cell patients with leg ulcers. Am J Hematol. 2011;86:705–8.
95.
De Castro LM, Jonassaint JC, Graham FL, Ashley-Koch A, Telen MJ. Pulmonary hypertension associated with sickle cell disease: Clinical and laboratory endpoints and disease outcomes. Am J Hematol. 2008;83:19–25.
96.
Naik RP, Streiff MB, Haywood C, Nelson JA, Lanzkron S. Venous Thromboembolism in Adults with Sickle Cell Disease: A Serious and Under-recognized Complication. Am J Med. 2013;126:443–9.
97.
Leveziel N, Bastuji-Garin S, Lalloum F, Querques G, Benlian P, Binaghi M, et al. Clinical and Laboratory Factors Associated With the Severity of Proliferative Sickle Cell Retinopathy in Patients With Sickle Cell Hemoglobin C (SC) and Homozygous Sickle Cell (SS) Disease. Medicine (Baltimore). 2011;90:372–8.
98.
Forrest S, Kim A, Carbonella J, Pashankar F. Proteinuria is associated with elevated tricuspid regurgitant jet velocity in children with sickle cell disease. Pediatr Blood Cancer. 2012;58:937–40.
99.
Lorch D, Spevack D, Little J. An Elevated Estimated Pulmonary Arterial Systolic Pressure, Whenever Measured, Is Associated with Excess Mortality in Adults with Sickle Cell Disease. Acta Haematol. 2011;125:225–9.
100.
Sachdev V, Kato GJ, Gibbs JSR, Barst RJ, Machado RF, Nouraie M, et al. Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. Circulation. 2011;124:1452–60.
101.
Ataga KI, Moore CG, Jones S, Olajide O, Strayhorn D, Hinderliter A, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol. 2006;134:109–15.
102.
Paul R, Minniti CP, Nouraie M, Luchtman-Jones L, Campbell A, Rana S, et al. Clinical correlates of acute pulmonary events in children and adolescents with sickle cell disease. Eur J Haematol. 2013;91:62–8.
103.
Gordeuk VR, Minniti CP, Nouraie M, Campbell AD, Rana SR, Luchtman-Jones L, et al. Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. Haematologica. 2011;96:33–40.
104.
Dham N, Ensing G, Minniti C, Campbell A, Arteta M, Rana S, et al. Prospective echocardiography assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease. Am J Cardiol. 2009;104:713–20.
105.
Darbari DS, Onyekwere O, Nouraie M, Minniti CP, Luchtman-Jones L, Rana S, et al. Markers of Severe Vaso-Occlusive Painful Episode Frequency in Children and Adolescents with Sickle Cell Anemia. J Pediatr. 2012;160:286–90.
106.
Liem RI, Young LT, Lay AS, Pelligra SA, Labotka RJ, Thompson AA. Reproducibility of tricuspid regurgitant jet velocity measurements in children and young adults with sickle cell disease undergoing screening for pulmonary hypertension. Am J Hematol. 2010;85:741–5.
107.
• Kato GJ. TRV: a physiological biomarker in sickle cell disease. Pediatr Blood Cancer. 2012;58:831–2. This is a recent article recommending a modified noninvasive echocardiogram screening protocol for children with sickle cell disease with suggested recommendations to consider invasive evaluation based on the tricuspid regurgitant jet velocity.
108.
Sachdev V, Machado RF, Shizukuda Y, Rao YN, Sidenko S, Ernst I, et al. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol. 2007;49:472–9.
109.
Lilje C, Harry J, Gajewski KK, Gardner R V. A modified noninvasive screening protocol for pulmonary hypertension in children with sickle cell disease-Who should be sent for invasive evaluation? Pediatr Blood Cancer. 2017;64:e26606.
110.
van der Land V, Peters M, Biemond BJ, Heijboer H, Harteveld CL, Fijnvandraat K. Markers of endothelial dysfunction differ between subphenotypes in children with sickle cell disease. Thromb Res. 2013;132:712–7.
111.
El-Shanshory M, Badraia I, Donia A, Abd El-hameed F, Mabrouk M. Asymmetric dimethylarginine levels in children with sickle cell disease and its correlation to tricuspid regurgitant jet velocity. Eur J Haematol. 2013;91:55–61.
112.
Elbarbary NS, Ismail EAR, Roushdy A, Fahmy E. Serum apelin as a novel non-invasive marker for subclinical cardiopulmonary complications in children and adolescents with sickle cell disease. Blood Cells, Mol Dis. 2016;57:1–7.
113.
Machado RF, Anthi A, Steinberg MH, Bonds D, Sachdev V, Kato GJ, et al. N-Terminal Pro-Brain Natriuretic Peptide Levels and Risk of Death in Sickle Cell Disease. JAMA. 2006;296:310.
114.
Voskaridou E, Tsetsos G, Tsoutsias A, Spyropoulou E, Christoulas D, Terpos E. Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. Haematologica. 2007;92:738–43.
115.
Mokhtar GM, Adly AAM, Alfy MS El, Tawfik LM, Khairy AT. N-Terminal Natriuretic Peptide and Ventilation-Perfusion Lung Scan in Sickle Cell Disease and Thalassemia Patients with Pulmonary Hypertension. Hemoglobin. 2010;34:78–94.
116.
Tantawy AAG, Adly AAM, Ismail EAR. Soluble CD163 in young sickle cell disease patients and their trait siblings. Blood Coagul Fibrinolysis. 2012;23:640–8.
117.
Adly AA, Ismail EA, Andrawes NG, Mahmoud MM, Eladawy R. Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease. Cytokine. 2016;79:52–8.
118.
Saleemi S. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension associated with hemolytic anemia. Ann Thorac Med. 2014;9:67.
119.
Almeida CB, Souza LEB, Leonardo FC, Costa FTM, Werneck CC, Covas DT, et al. Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. Blood. 2015;126:711–20.
120.
Olnes M, Chi A, Haney C, May R, Minniti C, Taylor J, et al. Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. Am J Hematol [Internet]. NIH Public Access. 2009;84:530–2.
121.
Gordeuk VR, Campbell A, Rana S, Nouraie M, Niu X, Minniti CP, et al. Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood. 2009;114:4639–44.
122.
Detterich JA, Kato RM, Rabai M, Meiselman HJ, Coates TD, Wood JC. Chronic transfusion therapy improves but does not normalize systemic and pulmonary vasculopathy in sickle cell disease. Blood. 2015;126:703–10.
123.
Covi S, Ravindranath Y, Farooqi A, Savasan S, Chu R, Aggarwal S. Changes in Bi-ventricular Function After Hematopoietic Stem Cell Transplant as Assessed by Speckle Tracking Echocardiography. Pediatr Cardiol. 2018;39:365–74.
124.
Dallas MH, Triplett B, Shook DR, Hartford C, Srinivasan A, Laver J, et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2013;19:820–30.
125.
Quimby KR, Hambleton IR, Landis RC. Intravenous infusion of haptoglobin for the prevention of adverse clinical outcome in Sickle Cell Disease. Med Hypotheses. 2015;85:424–32.
126.
Schaer CA, Deuel JW, Schildknecht D, Mahmoudi L, Garcia-Rubio I, Owczarek C, et al. Haptoglobin Preserves Vascular Nitric Oxide Signaling during Hemolysis. Am J Respir Crit Care Med. 2016;193:1111–22.
127.
Baek JH, D’Agnillo F, Vallelian F, Pereira CP, Williams MC, Jia Y, et al. Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. J Clin Invest. 2012;122:1444–58.
128.
Haw A, Palevsky HI. Pulmonary hypertension in chronic hemolytic anemias: Pathophysiology and treatment. Respir Med. 2018;137:191–200.
129.
Minniti CP, Machado RF, Coles WA, Sachdev V, Gladwin MT, Kato GJ. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. Br J Haematol. 2009;147:737–43.
130.
Sabaa N, de Franceschi L, Bonnin P, Castier Y, Malpeli G, Debbabi H, et al. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest. 2008;118:1924–33.
Metadaten
Titel
Pulmonary Hypertension in Children with Sickle Cell Disease: a Review of the Current Literature
verfasst von
Jamie K. Harrington
Usha S. Krishnan
Publikationsdatum
01.06.2019
Verlag
Springer US
Erschienen in
Current Pediatrics Reports / Ausgabe 2/2019
Elektronische ISSN: 2167-4841
DOI
https://doi.org/10.1007/s40124-019-00188-3

Weitere Artikel der Ausgabe 2/2019

Anomalous Left Coronary Artery from the Pulmonary Artery (ALCAPA): a Systematic Review and Historical Perspective

  • Cardiology (W Zuckerman and E Silver, Section Editors)

Modern Day Care of Patients With Single Ventricle Heart Disease: Late Complications of Fontan Palliation

  • Cardiology (W Zuckerman and E Silver, Section Editors)

Neurodevelopmental Outcomes in Children with Complex Congenital Heart Disease

  • Neonatology (C Juliano, Section Editor)

New Approaches to the Evaluation and Management of Well-Appearing Term and Late Preterm Neonates at Risk for Early-Onset Sepsis

  • Neonatology (C Juliano, Section Editor)

Neu im Fachgebiet Pädiatrie

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Einige Medikamente wie selektive Serotonin-Wiederaufnahmehemmer können offenbar die Makronährstoffzusammensetzung der Muttermilch verändern. Das birgt möglicherweise gesundheitliche Risiken für manche gestillte Kinder.

Kann man Gestationsdiabetes mit oralen Antidiabetika behandeln?

Der Wunsch, Frauen mit Gestationsdiabetes eine orale Erstlinientherapie anbieten zu können, bleibt auch vorläufig ein Wunsch: Eine orale Stufentherapie hat sich in einer randomisierten Studie nicht als gleichwertig zu einer Insulintherapie erwiesen. 

Frühwarnzeichen für multiple Sklerose bei Kindern und Jugendlichen

Ein Forschungsteam aus Deutschland und Kanada hat eine Reihe metabolischer, okulärer, muskuloskelettaler, gastrointestinaler und kardiovaskulärer Symptome identifiziert, die bei Kindern und Jugendlichen der Diagnose einer multiplen Sklerose (MS) vorausgehen können.

Harnwegsinfekte: Was taugt die antibiotische Kurzzeittherapie bei Kindern?

In einer aktuellen Metaanalyse wurde untersucht, wie erfolgsversprechend eine verkürzte Antibiotikatherapie bei afebrilen Kindern mit Harnwegsinfekten im Vergleich zur Standardtherapie ist. In gewissen Fällen könnte die Kurzzeittherapie ausreichen. 

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise